To evaluate TACE procedures regarding its efficacy and safety in our local institution; and identify possible predictors for TACE therapy that influence outcomes.
A retrospective analysis of 84 patients who received treatment with TACE for HCC between 2007 and 2015 at our centre was performed. Primary outcomes measured were progression-free survival, overall survival and complication rates.
The median progression-free survival was 12.0 months, with median overall survival time being 30.7 months. An alpha-fetoprotein (AFP) response ratio of greater than 50% was associated with better progression-free and overall survival. The patient’s Child-Pugh score and unilobar involvement also correlated with overall survival in multivariate analysis. No significant post procedural complications were encountered.
TACE is safe and effective in the management of HCC. A fall of 50% in AFP after TACE was predictive of better progression-free and overall survival.